Early Engagement On Outcomes-Based Deals Helps Unlock EU Access To Kymriah
Executive Summary
Novartis has managed to temporarily overcome payer reservations about the real-world value of Kymriah by engaging early with payers and heath technology assessment bodies and by developing tailored outcomes-based deals for key European markets. Approaching each payer with a responsible attitude has helped too.
You may also be interested in...
Payers Must Brace For Coming Wave Of Cell And Gene Therapies
One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of new cell and gene therapies over the next few years. Enzyvant, Novartis and Spark share how they are positioning their complex products.
Scottish HTA OKs Kymriah For Lymphoma After Novartis Drops Price
Scotland’s health technology assessment body has reversed its earlier decision to reject Kymriah for DLBCL.
Scottish HTA OKs Kymriah For Lymphoma After Novartis Drops Price
Scotland’s health technology assessment body has reversed its earlier decision to reject Kymriah for DLBCL.